Basic Information
Insulin aspart Sanofi
Regulatory Information
EMEA/H/C/005033
June 25, 2020
April 30, 2020
6
September 23, 2024
Company Information
France
82 Avenue Raspail 94250 Gentilly
SANOFI WINTHROP INDUSTRIE
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Insulin aspart Sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
Overview Summary
Insulin aspart Sanofi is a medicine used to control blood glucose (sugar) levels in patients from one year of age who have diabetes. Insulin aspart Sanofi is a ‘biosimilar medicine’. This means that Insulin aspart Sanofi is highly similar to another biological medicine (the ‘reference medicine’) that is already authorised in the EU. The reference medicine for Insulin aspart Sanofi is NovoRapid. Insulin aspart Sanofi contains the active substance insulin aspart, a rapid-acting insulin.